Roivant launches another 'Vant' company, this one to develop cellular therapies in Asia

4 April 2019
roivant_logo_big

Switzerland-based Roivant Sciences today announced the launch of Cytovant Sciences, a biopharmaceutical company focused on developing and commercializing innovative cellular therapeutics in Asia, together with its previously spun-out “vant” company Sinovant Sciences.

Cytovant will focus on development programs that have the potential to transform the treatment of diseases that are prevalent in Asian patients. Concurrent with the company’s launch, Cytovant has entered into a multi-program license and collaboration agreement with Germany’s Medigene (FSE: MDG1), a clinical stage biotechnology company focusing on the development of T cell immunotherapies.

News of the deal saw Medigene’s shares leap nearly 15% to 10.65 euros by late afternoon trading.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology